Management Team & Consultants

Lourdes Felix

One of the founders and President of BioCorRx Pharmaceuticals Inc., a commercial stage majority-owned subsidiary of BioCorRx Inc, that is focused on the commercialization and development of addiction treatments and related disorders. Responsible for recruitment of new regulatory staff members, leading planning of the Company’s plans and programs, patent filings, and identifying mergers and acquisitions opportunities. In 2025, she was responsible for negotiating and acquiring BioCorRx Pharmaceutical’s first FDA-approved commercialized drug. LUCEMYRA® (lofexidine).

30 years of combined experience in management, corporate finance, capital markets, public accounting, and the private sector. She has 14 years of executive leadership with BioCorRx Inc. Hands-on financial officer known for her deliberate and focused approach to limiting risk throughout startup and growth, with progression to CEO. Instrumental in capital procurement, completing in excess of forty million dollars in equity and nondilutive funding, and accomplished in structuring and negotiating transactions and favorable terms with investment banks and retail investors. Experienced in Securities and Exchange Commission filings with a deep understanding and proficiency in a critical area of financial reporting and compliance with public companies. Developed and launched BioCorRx Inc’s first weight loss program, UnCraveRx in 2019. Lourdes also has experience with addiction clinic operations management and deep expertise with medication-assisted treatment using naltrexone. For over 15 years, has helped people get into long-term recovery from opioids and alcoholism with BioCorRx’s B2B addiction treatment program, Beat Addiction Recovery.

Dr. Kate Beebe DeVarney

Director and Consultant for BioCorRx Pharmaceuticals, Inc. where she provides development and regulatory oversight and strategic direction for the company’s clinical stage assets, and leads medical affairs activities for a commercial stage product. Dr. DeVarney is also the Principal Investigator on two NIDA-funded development programs for the company’s lead asset, BICX104.

Dr. Kate DeVarney is an independent consultant with more than 30 years of experience in the pharmaceutical industry. Most recently, she served as the President, Chief Operating Officer and Director of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a US pharmaceutical company. She joined Titan in February 2007 and served as an Officer and member of the Titan Board since December 2019. During her 17 years with Titan, she held various senior executive positions with primary responsibility for oversight of product research and development, Regulatory and Medical Affairs. She led the development and global regulatory approval and US medical affairs of Probuphine, a six-month buprenorphine implant for the treatment of Opioid Use Disorder. Dr. DeVarney has been the Principal Investigator for four research grants from the National Institute on Drug Abuse (NIDA) and is currently a member of the National Advisory Council on Drug Abuse (NACDA).

As a Neuroscientist in the pharmaceutical industry, Dr. DeVarney has held a diverse range of positions of increasing responsibility within various public companies, including SmithKline Beecham, GlaxoSmithKline, Merck, Corcept Therapeutics and Tian Pharmaceuticals.

Before her pharmaceutical career, Dr. DeVarney was a hospital-based clinician and worked in academic medicine for 10 years before entering the pharmaceutical industry. She received her Ph.D. in Clinical Neuropsychology from George Mason University and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania.

Scott Henley, MBA

Consultant for BioCorRx Pharmaceuticals Inc. Scott has had a distinguished career in clinical operations and project management within the pharmaceutical industry, showcasing expertise across various therapeutic areas and organizational levels. Prior to joining BioCorRx Pharmaceuticals, Mr. Henley served as Vice President of Clinical Operations at Crinetics Pharmaceuticals. His contributions included implementing the company's first Phase 3 program, comprising two pivotal trials that produced excellent results and enrolled on time. In addition, Mr. Henley held key positions at Blade Therapeutics, Rigel Pharmaceuticals, and Titan Pharmaceuticals where he helped oversee clinical development, portfolio management, and clinical operations. He holds a Bachelor of Arts degree from the University of North Carolina, Chapel Hill, and a Master of Business Administration from Duke University, Durham, NC.

Dr. Raj Patel

Consultant for BioCorRx Pharmaceuticals Inc. Dr. Patel has extensive hands-on management experience in the design and development of various dosage forms for the pharmaceutical and biopharmaceutical industries spanning over 30-plus years. Specifically, about 20+ years in development, manufacturing, approval and commercial supply chain of 6-months or longer implantable products. With his combined comprehensive knowledge of formulation design and development and unique industrial pharmacy and pharmacokinetics background, he has successfully developed and helped to launch several products. His expertise includes solid dosage forms, such as tablets and capsules, liquid injectable and oral dosage forms, as well as novel delivery systems such as controlled and implantable drug delivery systems.

Dr. Steven M. Weisman

Lead Clinical and Regulatory Support Consultant. Dr. Weisman, a founder of Innovative Science Solutions and Head of Clinical and Regulatory Support, plays a leading role in guiding the Company through its anticipated FDA 505(b)(2) regulatory submission(s). Dr. Weisman has over 20 years of experience in pharmacology, toxicology, pharmaceutical product development, clinical and regulatory affairs, and marketing evaluation. As head of ISS' Clinical and Regulatory Support practice, he manages all aspects of the FDA advisory committee process for many of the largest pharmaceutical companies and represents companies before regulatory authorities around the world. He played a leading role in the removal of PPA (phenylpropanolamine) and analgesic Aleve, from a prescription-only product to over-the-counter form. Dr. Weisman received his PhD in Pharmacology from Cornell University Medical College and completed his postdoctoral training in Immunopharmacology at the Roche Institute of Molecular Biology.